{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:07:39Z","timestamp":1784750859329,"version":"3.55.0"},"reference-count":45,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["OPP1059029"],"award-info":[{"award-number":["OPP1059029"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MMV Medicines for Malaria Venture"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,3,2]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>\n                     <jats:italic>Plasmodium vivax<\/jats:italic> recurrence prevention using tafenoquine or primaquine is critical for achieving Thailand\u2019s malaria elimination targets. Both drugs may cause haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. This study evaluated the operational feasibility and safety of administering tafenoquine or primaquine after quantitative G6PD point-of-care testing in Thailand.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, observational, multicentre, longitudinal study was conducted between 23 May 2022 and 14 September 2023 during pilot implementation at seven sites in Yala and Mae Hong Son provinces. Eligible patients were \u226516 years old with uncomplicated <jats:italic>P. vivax<\/jats:italic> malaria. G6PD enzyme activity was quantified using a point-of-care device. All patients received 3-day chloroquine plus (based on G6PD enzyme activity): single-dose tafenoquine 300\u2009mg (\u22656.1\u2009U\/g Hb), or primaquine 15\u2009mg\/day for 14 days (\u22654.1\u2009U\/g Hb), or primaquine 45\u2009mg\/week for 8 weeks (\u22644.0\u2009U\/g Hb), with follow-up on days 5 and 14. Hospital admissions were reviewed to confirm acute haemolytic anaemia cases. The primary endpoint was the percentage of <jats:italic>P. vivax<\/jats:italic> patients \u226516 years old treated or not treated with tafenoquine in accordance with G6PD enzyme activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 316 <jats:italic>P<\/jats:italic>. <jats:italic>vivax<\/jats:italic> patients screened, 187 were enrolled. All patients completed quantitative G6PD testing. According to G6PD status, appropriate use or non-use was 100% (95% CI 97.2, 100 (132\/132)) with tafenoquine, 100% (95% CI 96.5, 100 (104\/104)) with daily primaquine and 99.5% (97.1, 100 (186\/187)) with weekly primaquine. At day 5, adverse events possibly related to haemolysis occurred in 46.3% (37\/80) of patients with tafenoquine, 56.8% (46\/81) with daily primaquine and 77.8% (14\/18) with weekly primaquine, with no confirmed drug-induced acute haemolytic anaemia cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Point-of-care quantitative G6PD testing prior to appropriate tafenoquine or primaquine administration was operationally feasible within the Thailand health system, with no concerning adverse events, supporting implementation of this treatment algorithm in areas of active <jats:italic>P. vivax<\/jats:italic> transmission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-016720","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:35:11Z","timestamp":1745476511000},"page":"e016720","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective observational study to assess the feasibility and safety of appropriate <i>Plasmodium vivax<\/i> radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct05753150","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1685-2141","authenticated-orcid":false,"given":"Prayuth","family":"Sudathip","sequence":"first","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nardlada","family":"Khantikul","sequence":"additional","affiliation":[{"name":"The Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aungkana","family":"Saejeng","sequence":"additional","affiliation":[{"name":"The Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Grewal Daumerie","sequence":"additional","affiliation":[{"name":"ImpactPlus, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lynch","sequence":"additional","affiliation":[{"name":"Independent regional advisor, Chaing Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Jambert","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saowanee","family":"Viboonsanti","sequence":"additional","affiliation":[{"name":"The Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Areechokchai","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerdsuda","family":"Kanjanasuwan","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thannika","family":"Thong-ard","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panupong","family":"Kowsurat","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borghini-Fuhrer","sequence":"additional","affiliation":[{"name":"MMV Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantana","family":"Padungtod","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025072914555508000_10.4.e016720.1","unstructured":"Mekong Malaria Elimination Programme . Epidemiology summary. 2022. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/366565\/WHO-UCN-GMP-MME-2023.01-eng.pdf?sequence=1"},{"key":"2025072914555508000_10.4.e016720.2","unstructured":"World Health Organization . World malaria report 2023. 2023. Available: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023"},{"key":"2025072914555508000_10.4.e016720.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-022-04229-z","article-title":"Assessing Thailand\u2019s 1-3-7 surveillance strategy in accelerating malaria elimination","volume":"21","author":"Sudathip","year":"2022","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12936-021-03740-z","article-title":"Implementation and success factors from Thailand\u2019s 1-3-7 surveillance strategy for malaria elimination","volume":"20","author":"Lertpiriyasuwat","year":"2021","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.5","doi-asserted-by":"crossref","first-page":"7799","DOI":"10.1038\/s41598-023-35007-9","article-title":"Projecting malaria elimination in Thailand using Bayesian hierarchical spatiotemporal models","volume":"13","author":"Rotejanaprasert","year":"2023","journal-title":"Sci Rep"},{"key":"2025072914555508000_10.4.e016720.6","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-397900-1.00002-5"},{"key":"2025072914555508000_10.4.e016720.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003890","article-title":"Clinical impact of vivax malaria: a collection review","volume":"19","author":"Phyo","year":"2022","journal-title":"PLoS Med"},{"key":"2025072914555508000_10.4.e016720.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003614","article-title":"Global economic costs due to vivax malaria and the potential impact of its radical cure: a modelling study","volume":"18","author":"Devine","year":"2021","journal-title":"PLoS Med"},{"key":"2025072914555508000_10.4.e016720.9","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2016.0048"},{"key":"2025072914555508000_10.4.e016720.10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.actatropica.2015.08.008","article-title":"Patients\u2019 adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border","volume":"152","author":"Cheoymang","year":"2015","journal-title":"Acta Trop"},{"key":"2025072914555508000_10.4.e016720.11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","article-title":"Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis","volume":"22","author":"Mehdipour","year":"2023","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010986","article-title":"Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: implications for 8-aminoquinoline radical cure","volume":"16","author":"Chamchoy","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025072914555508000_10.4.e016720.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802537"},{"key":"2025072914555508000_10.4.e016720.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710775"},{"key":"2025072914555508000_10.4.e016720.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00213-X"},{"key":"2025072914555508000_10.4.e016720.16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/FPC.0000000000000407","article-title":"Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria","volume":"30","author":"St Jean","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"2025072914555508000_10.4.e016720.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med"},{"key":"2025072914555508000_10.4.e016720.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002224","article-title":"Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens","volume":"14","author":"Chu","year":"2017","journal-title":"PLoS Med"},{"key":"2025072914555508000_10.4.e016720.19","unstructured":"Division of Vector Borne Diseases in the Ministry of Public Health, MMV Medicines for Malaria Venture . The ARCTIC study: optimizing P. vivax radical cure in Thailand. 2022. Available: https:\/\/www.vivaxmalaria.org\/training-resources\/resources\/arctic-study-optimizing-p-vivax-radical-cure-thailand"},{"key":"2025072914555508000_10.4.e016720.20","unstructured":"PMI US President\u2019s Malaria Initiative . Thailand malaria profile. 2022. Available: https:\/\/d1u4sg1s9ptc4z.cloudfront.net\/uploads\/2023\/01\/RDMA-Malaria-Profile-1.pdf"},{"key":"2025072914555508000_10.4.e016720.21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/tropicalmed4040143","article-title":"The evolution of the malaria clinic: the cornerstone of malaria elimination in Thailand","volume":"4","author":"Sudathip","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"2025072914555508000_10.4.e016720.22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12936-021-03791-2","article-title":"Progress and challenges of integrated drug efficacy surveillance for uncomplicated malaria in Thailand","volume":"20","author":"Sudathip","year":"2021","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12936-022-04363-8","article-title":"Modelling malaria in southernmost provinces of Thailand: a two-step process for analysis of highly right-skewed data with a large proportion of zeros","volume":"21","author":"Ammatawiyanon","year":"2022","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.24","first-page":"316","article-title":"Changes in malaria vector densities over a twenty-three year period in Mae Hong Son Province, northern Thailand","volume":"35","author":"Suwonkerd","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2025072914555508000_10.4.e016720.25","unstructured":"Ministry of Public Health . Malaria information system database. 2023. Available: https:\/\/malaria.ddc.moph.go.th\/malariaR10\/home.php"},{"key":"2025072914555508000_10.4.e016720.26","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0612"},{"key":"2025072914555508000_10.4.e016720.27","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.14208","article-title":"Prevalence of G6PD deficiency and G6PD variants amongst the southern Thai population","volume":"10","author":"Nuinoon","year":"2022","journal-title":"PeerJ"},{"key":"2025072914555508000_10.4.e016720.28","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2652-y"},{"key":"2025072914555508000_10.4.e016720.29","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9010"},{"key":"2025072914555508000_10.4.e016720.30","first-page":"576","article-title":"G-6-PD Mahidol. The most common glucose-6-phosphate dehydrogenase variant in Thailand","volume":"55","author":"Panich","year":"1972","journal-title":"J Med Assoc Thai"},{"key":"2025072914555508000_10.4.e016720.31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1532\/IJH97.A20513","article-title":"Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children","volume":"83","author":"Laosombat","year":"2006","journal-title":"Int J Hematol"},{"key":"2025072914555508000_10.4.e016720.32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12936-024-04864-8","article-title":"Genetic analysis and molecular basis of G6PD deficiency among malaria patients in Thailand: implications for safe use of 8-aminoquinolines","volume":"23","author":"Boonyuen","year":"2024","journal-title":"Malar J"},{"key":"2025072914555508000_10.4.e016720.33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3347\/kjp.2022.60.1.15","article-title":"Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among malaria patients in southern Thailand: 8 years retrospective study","volume":"60","author":"Khammanee","year":"2022","journal-title":"Korean J Parasitol"},{"key":"2025072914555508000_10.4.e016720.34","first-page":"187","article-title":"Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in northern Thailand","volume":"45","author":"Charoenkwan","year":"2014","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2025072914555508000_10.4.e016720.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003084","article-title":"Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: a systematic review and meta-analysis","volume":"17","author":"Pfeffer","year":"2020","journal-title":"PLoS Med"},{"key":"2025072914555508000_10.4.e016720.36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/2224-3151.213793","article-title":"Implementation of G6PD testing and primaquine for P. vivax radical cure: operational perspectives from Thailand and Cambodia","volume":"6","author":"Kitchakarn","year":"2017","journal-title":"WHO South East Asia J Public Health"},{"key":"2025072914555508000_10.4.e016720.37","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1784-1"},{"key":"2025072914555508000_10.4.e016720.38","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0779"},{"key":"2025072914555508000_10.4.e016720.39","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2214-109X(23)00542-9","article-title":"Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis","volume":"12","author":"Brito","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2025072914555508000_10.4.e016720.40","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04300-9"},{"key":"2025072914555508000_10.4.e016720.41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/pathogens12030400","article-title":"Glucose-6-phosphate dehydrogenase (G6PD) measurement using biosensors by community-based village malaria workers and hospital laboratory staff in Cambodia: a quantitative study","volume":"12","author":"Adhikari","year":"2023","journal-title":"Pathogens"},{"key":"2025072914555508000_10.4.e016720.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275822","article-title":"G6PD testing and radical cure for Plasmodium vivax in Cambodia: a mixed methods implementation study","volume":"17","author":"Kheang","year":"2022","journal-title":"PLoS ONE"},{"key":"2025072914555508000_10.4.e016720.43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/pathogens12050689","article-title":"Assessing the operational feasibility of integrating point-of-care G6PD testing into Plasmodium vivax malaria management in Vietnam","volume":"12","author":"Gerth-Guyette","year":"2023","journal-title":"Pathogens"},{"key":"2025072914555508000_10.4.e016720.44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","article-title":"Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study","volume":"24","author":"Brito","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025072914555508000_10.4.e016720.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012197"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-016720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T21:56:06Z","timestamp":1753826166000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-016720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,24]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjgh-2024-016720"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-016720","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}